http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006234300-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_36d5b16a33c21e84c5f3f920f08502c5 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-817 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6887 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate | 2005-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36ebf9d5fbebc267eda1361f48fb85b7 |
| publicationDate | 2006-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2006234300-A1 |
| titleOfInvention | Cardiac hormones for assessing cardiovascular risk |
| abstract | The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for adminitstration of a cox-2-inhibiting compound, in particular an NSAID, selective cox-2 inhibitior, or steroid. More particularly, the present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a selective cox-2 inhibitor, comprising the steps of (a) measuring, preferably in vitro, the level of a cardiac hormone, (b) diagnosing the risk of the patient by comparing the measured level to known levels associated with different grades of risk in a patient. The most preferred cardiac hormone in the context of the present invention is NT-proBNP. Furthermore, the present invention relates to a method for diagnosing the risk of a patient to suffer from a cardiovascular complication as a consequence of administration of a cox-2 inhibiting compound, comprising the steps of (a) measuring the level of a cardiac hormone, (b) diagnosing the risk of the patient by comparing the measured level to known levels associated with different grades of risk in a patient. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010279431-A1 |
| priorityDate | 2005-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 932.